An investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large conglomerate with several global offices has two sites in the US is actively seeking new investment opportunities. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and the new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A premier investment bank affiliated with a major conglomerate has an investment arm that invests across public, private, and mezzanine asset classes across various industries, including life sciences and healthcare. The firm is stage agnostic, but has invested in pre-Series A and Series A rounds and has an increased interest in early-stage technologies. Investments can be made out of the firms’ proprietary capital or through special purpose vehicles (SPVs). The firm is interested in global opportunities.

The firm is interested in all healthcare verticals: therapeutics, life science tools and diagnostics, medical devices, and digital health.  Within therapeutics, the firm is open to all types of modalities, indications, and therapeutic classes. The firm is stage agnostic and has invested in all rounds from pre-A to crossover rounds.

The firm has no specific company or management requirements. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, The firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, The firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 and is headquartered in the USA is currently on their second fund, and the typical check size is flexible, with a typical first check for coming at the seed through series A stage between $1M-5M. The firm is open to both leading or following the investments, but prefers to lead at the seed stage.  The firm focuses on companies located in the US.

The firm is looking for new investment opportunities in sectors focused on applied biology and chemistry, including the therapeutics and diagnostics sectors as well as sustainability, synthetic biology, agtech, and other industrial sectors. The firm is opportunistic in terms of sub-sectors and indications, including all phases of development for therapeutics and various use-cases of synthetic biology. The firm is not typically interested in healthcare services or healthcare IT.

The firm invests in companies in the US and likes to see second or third time entrepreneurs, however the firm will back bold first time entrepreneurs with compelling technologies. The firm is open to both leading or following the investment, and could seek a board seat in certain deals.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science research tools manufacturer based in Western Europe with offices worldwide is interested in partnering with companies developing cutting-edge products that are a strategic fit for the firm’s portfolio. The firm is looking for novel product line addition opportunities globally and possible investments in early stage companies located in North America or Europe who are pursuing technology-leading approaches in the firm’s selected application fields.

The firm is focused on investing in companies that are developing products used in research labs, including consumables, bioprocess and lab automation equipment, and digital tools used by research scientists. The firm generally invests in companies with products that are at the commercial stage. The firm is targeting emerging, non-public companies who are pursuing applications in the areas of Molecular Biology, AI/Digital and Cell Biology.

The firm is flexible about partnering structure and open to a range of approaches including licensing, co-development, equity investments and acquisitions. The firm is a first-for-the-company, corporate venture fund with a charter towards select, new business line-directed equity investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm and incubator that was established in 2020 and is headquartered in USA has about USD 50 million in assets under management. The firm prefers to participate in early-stage and seed (pre-Series A) financing as well as later-stage and pre-IPO (post-Series B and C) financing while avoiding the middle-stages. The firm manages an evergreen fund with between USD 10 million and USD 20 million of available capital per year. The firm typically makes around 3 or 4 investments per year with typical initial allocation size between USD 2 million and USD 10 million for early-stage companies and around USD 10 million for later-stage companies. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments and convertible loans. The firm primarily invests in companies based in the United States and China but is open to considering all global opportunities as well.

The firm is primarily interested in investing in companies in the biotechnology therapeutics and medical technology sectors. The firm will consider all modalities across these sectors but has expertise in molecule development and prefers to avoid medical devices. The firm has no experience in digital health but will consider investments in the diagnostics sector but prefers to focus on genomics and biomarker diagnostics. The firm will invest in therapeutics that are pre-clinical or in Phase I to Phase III of clinical trials as well as medical technology and diagnostics that are in development or clinical. The firm is disease agnostic and will consider companies across all indications but has experience investing in cancer and autoimmune related technologies.

The firm prefers to work with experienced management teams are dedicated to their technology and their company. The firm is an active investor and will take a board seat on a case-by-case basis depending on investment size. Plaisance Capital Management will act as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.